Page 1,846«..1020..1,8451,8461,8471,848..1,8601,870..»

Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas …

Posted: March 5, 2015 at 7:40 am

Southlake, Texas (PRWEB) March 05, 2015

RMI specializes in Stemnexa non-surgical treatment of acute and chronic orthopedic conditions such as meniscal tears, ACL injuries, rotator cuff injuries, runners knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. Stemnexa may also be administered during orthopedic surgeries to promote better post-surgical outcomes.

Stemnexa combines the latest, patented scientific advances in nearly pain-free bone marrow harvesting with two complimentary cellular technologies: Bone Marrow Aspirate Concentrate (BMAC) and *AlphaGEMS amniotic tissue product.

BMAC contains a patients own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS product is harvested from donated amniotic sac tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

Find out more about RMI in the February edition of Society Life Magazine.

Riordan-McKenna Institute

Riordan Medical Institute

801 E. Southlake Blvd. Southlake, Texas 76092

Tel: (817) 776-8155 Toll Free: (877) 899-7836 Fax: (817) 776-8154

Continued here:
Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas ...

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas …

Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and …

Posted: March 5, 2015 at 5:53 am

Novogen Limited (NVGN)

Shares of Novogen Limited (NVGN) touched an increase in value of more than 50% in extended-hours trading on Tuesday, after the company confirmed that its TRXE-009 is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer, based on findings from studies conducted at the Feinstein Institute for Medical Research, the research branch of North Shore-LIJ Health System.

The latest study looked at the ability of NVGN's TRXE-009 to kill a library of patient-derived cell cultures from subjects with glioblastoma multiform (GBM). These stemlike cancer cells are believed to be responsible for chemotherapy resistance and tumor recurrence, so killing these highly resistant GBM cancer stem cell is considered to be a fundamental requirement to successfully treating this highly destructive diseas

According to NVGN, all patient derived cancer cells represented in the library responded to TRXE-009 at clinically relevant doses, suggesting a strong therapeutic potential.

These findings, together with other results from recently announced pre-clinical studies, suggest that NVGN's TRXE-009 is a unique drug candidate in preferentially targeting tumors with a common embryonic origin in neural/neural crest cells.

NVGN is engaged in the pharmaceutical research and development business in Australia. NVGN group includes US-based CanTx Inc, a joint venture company with Yale University

More about Novogen Limited (NVGN) at http://www.novogen.com

**

eFuture Information Technology Inc. (EFUT)

Read more:
Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and ...

Posted in Michigan Stem Cells | Comments Off on Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and …

Derick Dillards Mom Cathy Gets Treatment To Keep Cancer At Bay, While Jill Suffers Morning Sickness

Posted: March 5, 2015 at 5:50 am

Parents-to-be Jill and Derick Dillard were sad his cancer survivor mother Cathy wouldnt be with them as they learned their babys gender on Tuesdays 19 Kids and Counting.

Cathy was getting ready to Omaha, Nebraska for treatment to prevent recurrence of her cancer and Jill made a cheesecake and snack care package for her mother-in-law.

As Jill recalled, Cathys battle with cancer dovetailed with the couples had happened when the couple got married last year, and they were overjoyed she was able to make it to the wedding.

PHOTOS: Jill Duggar and Derick Dillards Wedding Day Revealed!

On Tuesdays episode, Cathy chowed down on the food theyd brought and told Jill and Derick, Ill pack on more pounds in the next four days than I have in the last three months.

Jill told the cameras, It is hard for me to see Dericks mom go through these health problems, and yet I know shes very strong and has lots of people praying for her.

Cathy said she would get stem cell transplant of her own stem cells during the therapy.

PHOTOS: Beautiful Jill Duggar Proudly Bares Baby Bump In Blue In NYC

My mom will be going for treatment, doing some procedures to keep the chance of her cancer recurring to a minimum, Derick said. He added that looking forward to her first grandchild definitely gives her some incentive to get better.

Dillard said he and Jill would find out the gender of their baby in their Arkansas hometown while Cathy was in Omaha.

See the rest here:
Derick Dillards Mom Cathy Gets Treatment To Keep Cancer At Bay, While Jill Suffers Morning Sickness

Posted in Arkansas Stem Cells | Comments Off on Derick Dillards Mom Cathy Gets Treatment To Keep Cancer At Bay, While Jill Suffers Morning Sickness

FINITI Italian – Video

Posted: March 4, 2015 at 1:45 pm


FINITI Italian
FINITI contains the only proprietary blend of natural ingredients known to safely lengthen short telomeres and maintain healthy stem cells. It also protects your DNA, telomeres, and cells...

By: Rachel Cohen

Excerpt from:
FINITI Italian - Video

Posted in Stem Cell Videos | Comments Off on FINITI Italian – Video

STEPHEN HAWKING SPECIALS – Video

Posted: March 4, 2015 at 1:45 pm


STEPHEN HAWKING SPECIALS
We are paying homage to Stephen Hawkings we will be airing everything from his biography to stem cell research. Stay tuned for more of our favourite scientist. Subscribe: youtube.com/user/yourdisc...

By: Your Discovery Science

Read this article:
STEPHEN HAWKING SPECIALS - Video

Posted in Stem Cell Research | Comments Off on STEPHEN HAWKING SPECIALS – Video

Scientists move closer to creating cartilage from stem cells

Posted: March 4, 2015 at 12:47 am

Scientists have succeeded in producing cartilage formed from embryonic stem cells that could in future be used to treat the painful joint condition osteoarthritis.

In research funded by Arthritis Research UK, Professor Sue Kimber and her team in the Faculty of Life Sciences at The University of Manchester has developed a protocol under strict laboratory conditions to grow and transform embryonic stem cells into cartilage cells (also known as chondrocytes).

Professor Kimber said: This work represents an important step forward in treating cartilage damage by using embryonic stem cells to form new tissue, although its still in its early experimental stages.

Their research was published in Stem Cells Translational Medicine.

During the study, the team analysed the ability of embryonic stems cells to become precursor cartilage cells. They were then implanted into cartilage defects in the knee joints of rats.

After four weeks cartilage was partially repaired and following 12 weeks a smooth surface, which appeared similar to normal cartilage, was observed. Further study of this newly regenerated cartilage showed that cartilage cells from embryonic stem cells were still present and active within the tissue.

Developing and testing this protocol in rats is the first step in generating the information needed to run a study in people with arthritis. Before this will be possible more data will need to be collected to check that this protocol is effective and that there are no toxic side-effects.

But researchers say that this study is very promising as not only did this protocol generate new, healthy-looking cartilage but also importantly there were no signs of any side-effects such as growing abnormal or disorganised, joint tissue or tumours. Further work will build on this finding and demonstrate that this could be a safe and effective treatment for people with joint damage.

Chondrocytes created from adult stem cells are currently being experimentally used but as they cannot be currently be produced in large amounts the procedure is expensive.

With their huge capacity to proliferate, embryonic stem cells, which can be manipulated to form almost any type of mature cell, offer the possibility of high-volume production of cartilage cells. Their use would also be cheaper and applicable to greater number of arthritis patients, the researchers claim.

See the article here:
Scientists move closer to creating cartilage from stem cells

Posted in Stem Cells | Comments Off on Scientists move closer to creating cartilage from stem cells

Behind the scenes of the world's first commercial stem-cell therapy

Posted: March 4, 2015 at 12:44 am

Contrasto/eyevine

Biologist Graziella Pellegrini has worked on stem-cell therapy at four different Italian institutions, including a hospital run by priests.

Last month saw a major landmark for regenerative medicine: the first time that a stem-cell therapy beside the use of cells extracted from umbilical cords had been cleared for sale by any regulatory agency in the world. The European Commission approved Holoclar for use in cases of blindness caused by burning. The achievement is all the more remarkable because Holoclar was developed by a small laboratory in Italy, a country better known for its lack of support for life sciences and for its recent tolerance of an unproven stem-cell concoction, marketed by the Stamina Foundation, that claimed to be a panacea for many diseases. Nature talked to Graziella Pellegrini from the University of Modena about how she and her colleagues overcame the many obstacles to take the therapy from bench to bedside.

The surface of the cornea the transparent tissue that sits in front of the iris is constantly renewed in a healthy eye, to keep it smooth and clear. New corneal cells are generated from a niche of stem cells in the limbus, an area between the cornea and the white of the eye. But if the limbus is destroyed by burning, then the white of the eye grows over the cornea and becomes criss-crossed with blood vessels. This causes chronic pain and inflammation, as well as blindness.

I had seen patients who had starting seeing again after 20 years of blindness: how could I stop?

Holoclar treatment can help to reverse these symptoms by adding new stem cells to seed the regrowth of a transparent cornea. But there must be enough surviving limbus in one eye to allow 1 or 2 square millimetres of tissue to be extracted. This tissue is then cultivated on a support made from modified human fibrin (a biodegradable blood protein) under stringent clinical conditions until at least 3,000 stem cells have been generated. The culture, still on its fibrin scaffold, is transplanted into the injured eye, which has been scraped clear of the invading white, and from there stem cells seed the regrowth of a transparent cornea, free of blood vessels, within a year.

Only around 1,000 people annually in the whole of Europe will be eligible: burns victims who have become blind but whose eyes have not been too extensively destroyed.

It is always very hard to find research money in Italy. We had to uproot many times. I first started working on the concept of the therapy, with my colleague Michele De Luca, in 1990 when we were post-docs at the University of Genova studying the fundamental biology of epithelial cells the cells that form the sheets lining organs, and also the skin. In 1996, we moved to Rome to the Institute Dermopatico Immaculate, a hospital run by priests who were highly committed to research and who offered us wonderful facilities and access to patients. But in the end they did not want to support our eye work through to the clinic. So in 2002, we moved to the Veneto Eye Bank Foundation in Venice, which had an epithelial stem-cell laboratory. Then in 2008 we moved again, to the Centre for Regenerative Medicine Stefano Ferrari, which had been newly created at the University of Modena specifically to incubate such types of advanced therapy.

Italy is not supportive of biomedical research. Things might have been easier if we had not had to struggle so much. But I am Italian, and the best way to stimulate me to find a solution is to tell me I cant do something. And despite the problems, research into advanced therapies does have a history here. One of the worlds first gene-therapy trials on children with an immunodeficiency disorder was carried out in Milan.

We published the results of our first two patients both successes in 19971. That was proof of principle that the therapy could work. Our major clinical paper, on 112 patients, was published in 20102. Around 77% of the transplants were fully successful, and a further 13% partially successful.

View original post here:
Behind the scenes of the world's first commercial stem-cell therapy

Posted in Cell Therapy | Comments Off on Behind the scenes of the world's first commercial stem-cell therapy

A single target for microRNA regulation

Posted: March 3, 2015 at 7:01 pm

11 hours ago Bursting roundworm. Due to a defect in regulation of the let-7 target lin-41 the worm bursts and dies at the larval to adult transition. Green: seam cell nuclei, red: cell membranes.

It has generally been believed that microRNAs control biological processes by simultaneously, though modestly, repressing a large number of genes. But in a study published in Developmental Cell, a group of scientists led by Helge Grosshans have now shown that miRNAs can control the development of a roundworm through regulation of a single target.

The discovery, some 15 years ago, of the small RNA molecule let-7 opened up a whole new field of research. It became apparent that genes in a wide variety of organisms from roundworms to humans are regulated by a host of so-called microRNAs (miRNAs). In the development of the roundworm, let-7 plays a key role: if it is defective, the worm bursts and dies as a result of abnormal development of the sexual organs. Although in the meantime, much has been learned about the molecular mechanisms underlying miRNA function, it remained unclear how this dramatic effect of let-7 was to be explained.

An elegant study by a group led by Helge Grosshans at the FMI has now revealed how let-7 controls normal vulval development in the roundworm. Moreover, by showing that miRNAs can produce significant biological effects through regulation of one single target gene, these findings make a substantial contribution to current theories on the functioning of miRNAs.

It is known that miRNAs can bind many different messenger RNAs (mRNAs), thus repressing protein translation or facilitating mRNA degradation. However, as the effect is usually modest, it was assumed that the biological activity of miRNAs is mediated by coordinated repression of numerous different mRNAs.

The new study demonstrates that the dramatic effect of let-7 is attributable to interaction with lin 41 mRNA alone, although let-7 also regulates other mRNAs. These other interactions are, however, dispensable and inconsequential. Grosshans comments: "The finding that a microRNA can have such a dramatic effect through interaction with a single gene is new. What our study also shows is that it is not enough to measure the interaction of RNA molecules we need to elucidate how such interactions influence a specific function."

Here, the scientists benefited from a new genome editing technology known as CRISPR-Cas9, which allows base pairs to be replaced in a targeted fashion. As first author Matyas Ecsedi explains, "We were able to modify the binding of let-7 to specific mRNAs and then directly observe what effect this had on the development of the sexual organs." As well as providing new insights into the functioning of miRNAs, this approach has the potential to advance the safe and effective use of miRNAs for therapeutic purposes.

Evolutionarily conserved: let-7 and LIN-41

The rise of microRNA research was largely due to the fact that let-7 is evolutionarily well conserved i.e., it occurs in many different animals. It was thus clear that let-7 is not peculiar to the roundworm, but plays a role in various species. Over the years, let-7 was found to be universally important as a regulator of stem cell processes.

LIN-41/TRIM71 likewise occurs in various organisms, assuming a similar function in each case. In stem and progenitor cells, LIN-41 promotes cell division and prevents cell differentiation, while let-7 serves the opposite function and represses LIN-41. As a pair, let-7 and LIN-41 are therefore of great interest in the quest to improve our understanding of stem cell processes.

Read more:
A single target for microRNA regulation

Posted in Texas Stem Cells | Comments Off on A single target for microRNA regulation

Mario Camacho Alcocer Joins Global Stem Cells Group Faculty

Posted: March 3, 2015 at 6:58 pm

Miami, FL (PRWEB) March 03, 2015

GlobalStemCellsGroup.com has recruited Mario Camacho Alcocer to the companys growing faculty. Camacho Alcocer, a biomedical researcher and founding partner of Criogenix SA de CV in Queretaro, Mexico, will join GSCGs team of biomedical professors who will teach the Diplomat in Cell Therapy and Tissue Engineering program.

Criogenix SA de CV is a private company registered in the National Record of Scientific and Technological Institutions and Companies in Mexico (RENIECYT).

Camacho Alcocer will teach two-day, interactive training courses on adult stem cell extraction and re-integration to physicians and qualified medical practitioners who wish to learn and use the process in their practices.

Camacho Alcocer is accomplished in generating and applying new stem cell therapeutic protocols and technologies. His current research focuses on extracellular matrix interactions to regulate the dynamic of defined stem cells populations, with a goal to regenerate functional capabilities of specific tissues (or to develop tissues in vitro), as well as the development of specific scaffolds for cell culture. His research is central to Criogenix SA de CVs development of a major integral stem cell unit management system for therapeutic applications.

Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner.

In 2014, Global Stem Cells Group expanded its Regenestem Networks global presence to 20 countries. Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide.

Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

The Global Stem Cells Group is committed to the highest standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

Original post:
Mario Camacho Alcocer Joins Global Stem Cells Group Faculty

Posted in New Mexico Stem Cells | Comments Off on Mario Camacho Alcocer Joins Global Stem Cells Group Faculty

Telomeres and Ageing – Video

Posted: March 3, 2015 at 2:42 pm


Telomeres and Ageing
Telomeres and Aging For more details visit: http://www.amazingstemcells.net FINITI naturally enhances the enzyme (telomerase) needed to lengthen our short telomeres.* This adds healthy life...

By: Jeunesseglobalteam

Continued here:
Telomeres and Ageing - Video

Posted in Stem Cell Videos | Comments Off on Telomeres and Ageing – Video

Page 1,846«..1020..1,8451,8461,8471,848..1,8601,870..»